Development and validation of a cisplatin dose-ototoxicity model

Journal of the American Academy of Audiology

Volumn 23, Issue 7, 2012, Pages 510-521

  Dille, Marilyn F ^a,b   Wilmington, Debra ^a,b,d   McMillan, Garnett P ^a,c   Helt, Wendy ^a   Fausti, Stephen A ^a,b   Konrad Martin, Dawn ^a,b  

^a NATIONAL CENTER FOR REHABILITATIVE AUDITORY RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cisplatin; Ototoxicity; Ototoxicity monitoring; Veterans

Indexed keywords

CISPLATIN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; HEARING LOSS; HUMAN; MALE; ONCOLOGICAL PARAMETERS; OTOTOXICITY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SAMPLE; SENSITIVE RANGE FOR OTOTOXICITY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; VALIDATION STUDY; VETERAN;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEARING; HEARING LOSS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 84864536563     PISSN: 10500545     EISSN: None     Source Type: Journal    
DOI: 10.3766/jaaa.23.7.3     Document Type: Article

References (44)

1. American Academy of Audiology (Academy). (2009) American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. http://www.audiology.org/resources/documentlibrary/Documents/ OtoMonGuidelines.pdf.
2. American Joint Committee on Cancer (AJCC). (2010) Cancer Staging Manual. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, III, eds. New York: Springer.
3. American Speech-Language-Hearing Association Ad Hoc Committee on Audiologic Management of Individuals Receiving Ototoxic and/or Vestibulotoxic Drug Therapy. (1994) Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy. http://www.asha.org/docs/html/GL1994-00003.html.
4. Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. (2009) Cisplatin-based chemotherapy: add high-frequency audiometry in the regimen. Indian J Cancer 46(4):311-317.
5. Bertolini P, Lassalle M, Mercier G, et al. (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26(10):649-655.
6. Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. (2007) Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67(2):469-479.
7. Biro K, Noszek L, Prekopp P, et al. (2006) Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emissions. Oncology 70:177-184.
8. Bokemeyer C, Berger CC, Hartmann JT, et al. (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77(8):1355-1362.
9. Carhart R, Jerger J. (1959) Preferred method for clinical determination of pure-tone thresholds. J Speech Hear Disord 24:330-345.
10. Collett D. (1991) Modelling Binary Data. London: Chapman and Hall.
11. de Jongh FE, van Veen RN, Veltman SJ, et al. (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88(8):1199-1206.
12. Dille MF, McMillan GP, Reavis KM, Jacobs P, Fausti SA, Konrad- Martin D. (2010a) Multivariate ototoxicity risk assessment combining distortion-product otoacoustic emissions with a cisplatin dose model. J Acoust Soc Am 128:1163-1174.
13. Dille MF, Konrad-Martin D, Gallun F, et al. (2010b) Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study. J Am Acad Audiol 21:409-417.
14. Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE. (1979) A system for evaluating auditory function from 8000-20 000 Hz. J Acoust Soc Am 66(6):1713-1718.
15. Fausti SA, Frey RH, Henry JA, Knutsen JL, Olson DJ. (1990) Reliability and validity of high-frequency (8-20 kHz) thresholds obtained on a computer-based audiometer as compared to a documented laboratory system. J Am Acad Audiol 1(3):162-170.
16. Fausti SA, Henry JA, Helt WJ, et al. (1999) An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear 20(6):497-505.
17. Fitzmaurice GN, Laird N, Ware J. (2004) Applied Longitudinal Analysis. Hoboken, NJ: John Wiley.
18. Fosså SD, de Wit R, Roberts JT, et al.; European Organization for Research and Treatment of Cancer Genitourinary Group 30941; Medical Research Council Testicular Cancer Study Group TE20. (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21(6):1107-1118.
19. Gorga MP, Dierking DM, Johnson TA, Beauchaine KL, Garner CA, Neely ST. (2005)Avalidation and potential clinical application of multivariate analyses of distortion-product otoacoustic emission data. Ear Hear 26(6):593-607.
20. Hallmark RJ, Snyder JM, Jusenius K, Tamimi HK. (1992) Factors influencing ototoxicity in ovarian cancer patients treated with Cisplatinum-based chemotherapy. Eur J Gynaecol Oncol 13(1):35-44.
21. Hellberg V, Wallin I, Eriksson S, et al. (2009) Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 101(1):37-47.
22. Helson L, Okonkwo E, Anton L, Cvitkovic E. (1978) cis-Platinum ototoxicity. Clin Toxicol 13(4):469-478.
23. Jacobs PG, Silaski G, Wilmington D, Gordon S, Ellingson RM, Helt W, McMillan G, Fausti SA, Dille MF. (Forthcoming) Development and evaluation of a portable telemedicine audiometer for high frequency screening of hearing loss from ototoxicity. IEEE Trans Biomed Eng.
24. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. (1988) Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98(8, Pt. 1):858-864.
25. Laurell G, Jungnelius U. (1990) High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100(7):724-734.
26. Laurell G, Viberg A, Teixeira M, Sterkers O, Ferrary E. (2000) Blood-perilymph barrier and ototoxicity: an in vivo study in the rat. Acta Otolaryngol 120(7):796-803.
27. Li Y, Womer RB, Silber JH. (2004) Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40(16):2445-2451.
28. Marshall NE, Ballman KV, Michalak JC, et al. (2006) Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neurooncol 77(3):315-320.
29. Mencher GT, Novotny G, Mencher L, Gulliver M. (1995) Ototoxicity and irradiation: additional etiologies of hearing loss in adults. J Am Acad Audiol 6(5):351-357.
30. Mukherjea D, Whitworth CA, Nandish S, Dunaway GA, Rybak LP, Ramkumar V. (2006) Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. Neuroscience 139(2):733-740.
31. Obuchowski NA. (1997) Nonparametric analysis of clustered ROC curve data. Biometrics 53(2):567-578.
32. Pepe M. (2003) The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, UK: Oxford University Press.
33. Reavis KM, McMillan G, Austin D, et al. (2011) Distortion-product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear 32(6):1-74.
34. Reavis KM, Phillips DS, Fausti SA, et al. (2008) Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear 29(6):875-893.
35. Ress BD, Sridhar KS, Balkany TJ, Waxman GM, Stagner BB, Lonsbury-Martin BL. (1999) Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg 121:693-701.
36. Riedemann L, Lanvers C, Deuster D, et al. (2008) Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8(1):23-28.
37. Rybak LP. (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15(5):364-369.
38. Schaefer S, Post JD, Close L, Wright C. (1985) Ototoxicity of low-and moderate-dose cisplatin. Cancer 56:1934-1939.
39. Schweitzer VG. (1993) Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103(4, Pt. 2):1-52.
40. Seligmann HL, Podoshin L, Ben-David J, Fradis M, Goldsher M. (1996) Drug-induced tinnitus and other hearing disorders. Drug Saf 14(3):198-212.
41. Truong MT, Winzelberg J, Chang KW. (2007) Recovery from cisplatin-induced ototoxicity: a case report and review. Int J Pediatr Otorhinolaryngol 71(10):1631-1638.
42. Vaughan NE, Fausti SA, Chelius S, Phillips D, Helt WJ, Henry JA. (2002) An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity. J Rehabil Res Dev 39(5):567-574.
43. Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM. (1983) Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19(1):53-58.
44. Wilmington D, Konrad-Martin D, Helt WJ, Dille MF, Gordon JS, Fausti SA. (2010) Ototoxicity monitoring: program approaches and considerations. Semin Hear 32(3):248-261.